Research Funding

Indo-Hungarian Joint Research Project worth 32.56 Lakh INR and 6 crore HUF by Indo-Hungarian Strategic Research Fund (IHSRF), being supported by DST, Governments of India and Government of Hungary.

Research & Publication

Citations 631, h-index 11, i-10 index 13 (Google Scholar ID: qJuXBscAAAAJ), 60 publications, 9 patents, 1 under consideration for technology transfer, 1 book & 1 book chapter. ORCID iD 0000-0001-6797-4561; Scopus Author ID: 57200732318

Ph.D. Students Guided

1. Design and Development of Pulsatile Drug Delivery System – Abhijit Sonje (2014)
2. Evaluation and Development of Anti-Diabetic Polyherbal Formulation of Indian Medicinal Plants – Rekha Rajput (2014)
3. Development and evaluation of transdermal patches for the treatment of central nervous disorders – Dashrath Singh (2017)
4. Formulation and evaluation of gastro retentive dosage forms for treatment of peptic ulcer – Ritesh Kumar (2018)
5. Silver Nanoparticle Loaded Microemulsion For Cancer Therapy – Anupama (2018)
6. Analytical method development and validation of inherent stability indicating RP-HPLC method for the simultaneous determination of related substances, assay of cabazitaxel and content in cabazitaxel injection dosages form – Alok Kumar Singh (2019)
7. Method development and validation by RP-HPLC for the determination of related substances and In-Vitro release of Lercanidipine Hydrochloride in Lercanidipine Hydrochloride Tablet –Anjali Lata Singh (2019)
8. Pricing regulation of prescription drug and its analysis across regulated and less regulated markets – Neeta Singh (2019)

 

M.Pharm Thesis Guided

  1. Transdermal drug delivery system: Effect of various penetration enhancers – Mr. Ashish Rai, M.Pharm, Bundelkhand University, Jhansi (2006).
  2. Effect of penetration enhancers on percuteneous absorption of salbutamol sulphate – Mr. Ashish Sirvastava, M.Pharm, Bundelkhand University, Jhansi (2006).
  3. Penetration enhancement studies of organogels of oxytetracycline hydrochloride – Ms. Nandani Chauhan, M.Pharm, Rajiv Academy for Pharmacy, Mathura.
  4. Functionalization of carbon nanostructures for non-viral gene delivery – Mr. Shashank Shaikhar, M.Pharm, Amity University, Noida (2012)
  5. Silymarin and Naringenin protect lead induced oxidative stress in rats – Ms. Deepali Saxena, M.Pharm, Amity University, Noida (2012)
  6. Histopathological study of breast cancer – Mr. Keshav Sharma, M.Pharm, Amity University, Noida (2012)
  7. Gene delivery via cationic vector – Mr. Jagjit Singh, M.Pharm, Amity University, Noida (2012)
  8. Immunological & toxicological studies of Abrin isolated from Abrus pecatorius – Ms. Priyanka Singh, M.Pharm, Amity University, Noida (2014)
  9. Biogenic formation of silver nanoparticles, its characterization and in-vivo anthelmintic activity – Mr. Rahul Mathur (2014)
  10. Development and characterization of solid lipid nanoparticles loaded with Arnebia nobilis root extract – Mr Sajan Raizada (2016)
  11. Optimization and characterization o Ratanjot loaded chitosan coated nanoparticles – Mr Akash Mishra (2016)
  12. Nanoemulsion as a vehicle in transdermal drug delivery system of NSAIDs – Mr Kshitij Vinod, AUUP (2016)
  13. Setting up GMP compliant pharmaceutical manufacturing plant in SEZ in India – Mr Ankit Nanda, AUUP (2018)
  14. Evaluation of 2D printing technology on edible wafer sheet for drug delivery of diclofenac sodium and chlorpromazine hydrochloride – Ms Navalika  (2018)
  15. Global regulatory registration requirement of medical devices – Ms Damini Sharma (2019)
  16. Switching of medicinal product from prescription to non-prescription – Ms Shivalika Behl, AUUP (2019)
  17. Product life cycle management as per US FDA – Mr Shivkant Sharma, AUUP (2019)
  18. Formulation and evaluation of Herbal effervescent tablets for cleaning denture base – ms Anamika Kumari, AUUP (2019)

UNDER TECHNOLOGY TRANSFER

The patented wound healing gel is 163 times more cost-effective is under consideration by a Pharmaceutical company for technology transfer has also been selected by Amity as top 20 patents for technology transfer

 Advantage

The current drug of choice is silver sulfadiazine (SS) used at 1%w/w in the form of cream. There is another line of treatment which uses 0.2%w/w silver nitrate(SN). There is a three-fold difference in the cost of SS & SN & our product uses 0.02%w/w silver nitrate, and therefore a 30 fold cost advantage.

 Unique selling point

  • First in line advantage,
  • Economically cheaper
  • Based on herbal drug
  • Better target audience acceptability
  • Physician acceptability as this is a product based on nano-silver.